The firm's reagents and disposables business was the biggest gainer, with a 12 percent revenue increase in the quarter.
The firm saw decreases in its core diagnostics business that were offset in part by revenues from newly-acquired Magellan Diagnostics.
The test, which will be based on AmoyDx's proprietary real-time PCR technology, will identify cancer-associated mutations in the RAS gene family.
Sales of the firm's infectious disease and women's health products were credited with driving the year-over-year increase in revenues.
The firm launched the multiplex PCR-based test this week on its Spartan Cube platform to support patient enrollment in Alzheimer's clinical trials.
In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.
Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.
Olympic athletes this summer will also undergo gene doping testing, according to Wired.
A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.